FRED HUTCHINSON CANCER CENTER
🇺🇸United States
MMF for HIV Reservoir Reduction
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03262441
- Locations
- 🇺🇸
2 West Clinic at Harborview Medical Center, Seattle, Washington, United States
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT03246906
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Phase 4
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT03238703
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2
Terminated
- Conditions
- Hematopoietic Cell Transplantation RecipientSecondary MyelofibrosisT-Cell Non-Hodgkin LymphomaAcute Biphenotypic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeukemiaHematologic and Lymphocytic DisorderVenous ThromboembolismChronic Myelogenous Leukemia, BCR-ABL1 PositiveMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03195010
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Mindset Intervention for Nicotine Dependence
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 398
- Registration Number
- NCT03174730
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Phase 1
Suspended
- Conditions
- Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT03128034
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 548
- Registration Number
- NCT03125070
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Phase 1
Terminated
- Conditions
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent B Acute Lymphoblastic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory B Acute Lymphoblastic LeukemiaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT03103971
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Communicating Health Information and Improving Coordination With Primary Care
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 347
- Registration Number
- NCT03104543
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT03074318
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
© Copyright 2024. All Rights Reserved by MedPath